Letrozole in Uterine Leiomyosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

July 30, 2028

Study Completion Date

July 30, 2029

Conditions
Uterine Leiomyosarcoma
Interventions
DRUG

Letrozole

Letrozole 2.5 mg PO daily

Trial Locations (13)

19090

RECRUITING

Asplundh Cancer Pavilion, Willow Grove

27834

RECRUITING

East Carolina University Health Medical Center, Greenville

33140

RECRUITING

Mount Sinai Comprehensive Cancer Center, Miami Beach

60201

RECRUITING

Endeavor Health - Kellogg Cancer Center, Evanston

71103

RECRUITING

WK Physician Network-Gynecologic Oncology Associates, Shreveport

73104

RECRUITING

University of Oklahoma Health Stephenson Cancer Center, Oklahoma City

80045

RECRUITING

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

80129

RECRUITING

Highlands Ranch Hospital, Highlands Ranch

87131

RECRUITING

University of New Mexico Comprehensive Cancer Center, Albuquerque

89106

RECRUITING

Women's Cancer Center of Nevada, Las Vegas

89511

RECRUITING

Women's Cancer Center of Nevada, Las Vegas

01605

RECRUITING

University of Massachusetts Memorial Medical Center, Worcester

02905

RECRUITING

Woman and Infants Hospital of Rhode Island, Providence

All Listed Sponsors
lead

GOG Foundation

NETWORK